Cold Chain: Delivering Innovative Specialty Pharmaceutical Products
Over the last decade, we have seen a proliferation of complex, temperature-sensitive specialty drugs—like biologic medicines and cell and gene therapies—that require cold chain handling. In fact, in 2018, half of the drugs approved by the US Food and Drug Administration (FDA) were temperature-sensitive products.
As the pipeline of specialty pharmaceutical products has increased in recent years, pharma companies and logistics providers have made significant investments in cold chain infrastructure, packaging solutions and technology capabilities to support the secure and reliable distribution of these products around the world.
For the full article from Rafael Teixeira, visit Pharmaceutical Commerce.